Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Birmingham Post
Birmingham Post
Business
Jon Robinson

Dechra Pharmaceuticals issues profit warning as £4.6bn takeover talks continue

Dechra Pharmaceuticals has issued a profit warning as talks over a possible £4.6bn takeover deal continue.

The Northwich-based vet products group has issued a statement to the London Stock Exchange amid the negotiations with Swedish private equity firm EQT.

EQT has until 5pm on June 2 to either make a firm offer or walk away.

READ MORE: Click here to sign up to the BusinessLive North West newsletter

In the statement, Dechra said its full-year underlying operating profit for the year to June 30, 2023, will be below its previously guided £186m.

It said: "The board is confident that Dechra's end customer demand has continued to be ahead of the animal health market in its major geographies.

"However, the trading environment during the period January to April 2023 has been more volatile and challenging than anticipated when the board reported its interim results on 27 February 2023.

"In the US, the impact of the now widely reported de-stocking by US wholesalers has been deeper and longer than initially expected and had a material impact on Q3 (January to March 2023) performance, although there are encouraging signs that this is now re-bounding.

"We have continued to see strong end customer demand as evidenced by product sales from wholesalers out to veterinary clinics, independent data for which shows year-on-year sales are up approximately 11% during the period January to April 2023.

"A similar de-stocking pattern has also been experienced in the UK during April 2023, due to certain wholesalers managing financial year-end inventory levels, although order patterns are beginning to show signs of normalising.

"In the rest of Europe, the market appears to be slowing in response to the changing macro-economic environment and country specific dynamics."

It added: "The board is confident that the group remains very well positioned to continue to grow over the medium and longer term despite the unprecedented and, by nature, short term trading headwinds.

"The fundamentals of the business and strategy remains strong, our underlying markets remain in structural growth, we continue to grow in our chosen markets and we have an established, highly experienced and focused management team.

"Our strategy is robust, including a very attractive development pipeline of new products to underpin our future growth, supported by a strong balance sheet."

READ MORE:

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.